Shanghai Chest Hospital
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 1957-01-01
- Employees
- -
- Market Cap
- -
Rh-Endostatin Combined With CCRT(50 Gy) Followed by Durvalumab Maintenance for the Treatment of Specific Phase III NSCLC
Phase 4
- Conditions
- Lung Cancer
- Interventions
- Drug: Recombinant human endostatin (Endostar)Radiation: Thoracic irradiation of 50 Gy with 3DCRT or IMRT
- First Posted Date
- 2020-11-03
- Last Posted Date
- 2020-11-03
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 97
- Registration Number
- NCT04613284
Evaluate the Diagnostic Value of BTPNA for PPL: a Real-world Study
Recruiting
- Conditions
- Peripheral Pulmonary Lesion
- First Posted Date
- 2020-10-22
- Last Posted Date
- 2023-02-23
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT04597346
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
Diagnostic Value of UTB and TB for PPL
Not Applicable
Completed
- Conditions
- Peripheral Pulmonary Lesion
- Interventions
- Procedure: Ultrathin bronchoscopeProcedure: Thin bronchoscopeProcedure: Virtual bronchoscopic navigation combined with endobronchial ultrasoundProcedure: Guide sheath
- First Posted Date
- 2020-10-01
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 578
- Registration Number
- NCT04571476
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
Nivolumab Combined With Anlotinib as Re-challenge Treatment in Advanced NSCLC
Phase 1
Completed
- Conditions
- NSCLC Stage IVCheckpoint Inhibitor
- Interventions
- First Posted Date
- 2020-08-11
- Last Posted Date
- 2022-06-28
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 21
- Registration Number
- NCT04507906
- Locations
- 🇨🇳
Shanghai Chest hospital, Shanghai, Shanghai, China
Dacomitinib in Lung Cancer With Uncommon EGFR Mutations
Phase 2
- Conditions
- Non-small Cell Lung Cancer MetastaticEGF-R Positive Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2020-08-07
- Last Posted Date
- 2022-06-28
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT04504071
- Locations
- 🇨🇳
Shanghai Chest hospital, Shanghai, Shanghai, China
Prediction Model of Peripheral Pulmonary Lesions Based on R-EBUS Image
- Conditions
- Diagnoses Disease
- First Posted Date
- 2020-08-04
- Last Posted Date
- 2020-08-04
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 1300
- Registration Number
- NCT04497233
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, China
The Chinese Registration Study of Driver Ablation of Persistent Atrial Fibrillation.
Not Applicable
Completed
- Conditions
- Atrial Fibrillation, Persistent
- Interventions
- Procedure: Stepwise ablationProcedure: Driver ablation+CPVI
- First Posted Date
- 2020-07-28
- Last Posted Date
- 2023-02-06
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 1298
- Registration Number
- NCT04489004
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, China
Cardiac Adverse Reactions Related to Immune Checkpoint Inhibitor in NSCLC Patients
- Conditions
- Adverse ReactionsImmune Checkpoint InhibitorCardiac EventNon-Small Cell Lung Cancer Patients
- Interventions
- Drug: renin-angiotensin system inhibitors or angiotensin-receptor-neprilysin inhibitor
- First Posted Date
- 2020-07-16
- Last Posted Date
- 2020-07-16
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT04473703
cfDNA Methylation Assay for Clinical Evaluation of Patients With Stage IA Lung Cancer After Ablation Operation
Not Applicable
- Conditions
- Lung Cancer
- Interventions
- Other: surgeryOther: ablation
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2020-06-04
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT04413656
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC
Phase 2
Recruiting
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2020-05-28
- Last Posted Date
- 2021-11-22
- Lead Sponsor
- Shanghai Chest Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT04405674
- Locations
- 🇨🇳
Shanghai Chest Hospital, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath